Aman U. Buzdar

Q: What Schools Are Affiliated With Aman U. Buzdar

Aman U. Buzdar is affiliated with the following schools: MD Anderson Cancer Center, University College London, University of Newcastle , University of British Columbia, Istanbul University, Queen's University at Kingston, University of Edinburgh, Baylor College of Medicine, Queen Mary University of London, University of Washington

Aman U. Buzdar's AcademicInfluence.com Rankings

Aman U. Buzdar

Philosophy

#3821

World Rank

#6111

Historical Rank

Logic

#1435

World Rank

#2186

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Aman U. Buzdar's Degrees

PhD Biomedical Sciences University of California, San Francisco
Doctorate Medicine Stanford University

Why Is Aman U. Buzdar Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Aman U. Buzdar's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Tamoxifen for early breast cancer: an overview of the randomised trials (1998) (3764)
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer (2005) (2258)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. (2010) (1458)
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. (1999) (1301)
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. (2007) (1171)
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. (2005) (1123)
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. (2000) (1005)
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. (1991) (903)
Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women (1988) (842)
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. (1999) (782)
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. (2010) (730)
Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. (1996) (723)
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. (2006) (714)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. (2008) (687)
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer (2003) (684)
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. (2010) (666)
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. (2011) (666)
Breast carcinoma in men (2004) (592)
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. (2006) (561)
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. (2010) (518)
Is breast cancer survival improving? (2004) (492)
Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. (1980) (486)
Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy (1988) (476)
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma (1998) (459)
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. (2006) (433)
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. (2008) (420)
Use of tamoxifen for breast cancer: twenty-eight years later. (1995) (411)
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. (2005) (400)
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. (1996) (397)
Multicenter, Phase II study of capecitabine in taxane‐pretreated metastatic breast carcinoma patients (2001) (396)
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. (1995) (385)
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. (2017) (383)
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. (2007) (380)
Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. (2000) (374)
Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. (2005) (369)
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. (2008) (358)
Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. (1999) (348)
Pathological assessment of response to induction chemotherapy in breast cancer. (1986) (344)
Inflammatory breast cancer: a review. (1992) (332)
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor‐positive breast cancer (2006) (331)
Residual risk of breast cancer recurrence 5 years after adjuvant therapy. (2008) (327)
Management of breast cancer during pregnancy using a standardized protocol. (1999) (306)
Breast Cancer in Men (2002) (306)
Early and delayed clinical cardiotoxicity of doxorubicin (1985) (291)
Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. (2005) (288)
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. (2000) (284)
Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes (2009) (271)
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients (2012) (266)
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. (2008) (261)
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women (2003) (260)
Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. (2004) (259)
‘Chemobrain’ in breast carcinoma? (2004) (255)
An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane (2002) (255)
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. (1999) (247)
Inflammatory breast carcinoma incidence and survival (1998) (245)
Accuracy of Physical Examination, Ultrasonography, and Mammography in Predicting Residual Pathologic Tumor Size in Patients Treated With Neoadjuvant Chemotherapy (2006) (244)
Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center (1997) (240)
Multimodal treatment of locoregionally advanced breast cancer (1983) (233)
Anastrozole is superior to tamoxifen as first‐line therapy in hormone receptor positive advanced breast carcinoma (2001) (233)
A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma (1997) (206)
Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer (2010) (199)
Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. (1996) (198)
Estrogen Receptors and Distinct Patterns of Breast Cancer Relapse (2003) (196)
Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma (1989) (195)
Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2‐positive breast cancer (2010) (192)
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. (2005) (191)
Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. (2008) (190)
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. (2001) (185)
Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. (2002) (185)
Phase II evaluation of Ly156758 in metastatic breast cancer. (1988) (185)
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. (2008) (181)
Obesity as an Adverse Prognostic Factor for Patients Receiving Adjuvant Chemotherapy for Breast Cancer (1994) (181)
Total RNA yield and microarray gene expression profiles from fine‐needle aspiration biopsy and core‐needle biopsy samples of breast carcinoma (2003) (179)
Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence (2004) (178)
Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. (1997) (178)
Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. (1990) (178)
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. (2003) (176)
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. (2002) (175)
Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. (1996) (173)
Adjuvant systemic therapy for male breast carcinoma (2005) (172)
Which threshold for ER positivity? a retrospective study based on 9639 patients. (2014) (171)
The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. (1989) (171)
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. (2000) (169)
Female patients with breast carcinoma age 30 years and younger have a poor prognosis (2001) (165)
Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. (2008) (164)
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. (2001) (157)
Clinical course of breast cancer patients with liver metastases. (1987) (156)
Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. (1997) (156)
Multivariate analysis of prognostic factors in metastatic breast cancer. (1983) (154)
Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. (2008) (152)
The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. (2004) (150)
Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response (2004) (149)
Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. (1998) (148)
Impact of Preoperative Versus Postoperative Chemotherapy on the Extent and Number of Surgical Procedures in Patients Treated in Randomized Clinical Trials for Breast Cancer (2006) (144)
Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. (1995) (143)
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. (2013) (142)
Inflammatory breast cancer (IBC) and patterns of recurrence (2007) (142)
Update on the management of inflammatory breast cancer. (2003) (138)
Results and long term follow‐up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin‐containing chemotherapy (1999) (137)
Estrogen receptor: A prognostic factor in breast cancer (1981) (135)
Causes of death in breast cancer a clinicopathologic study (1980) (132)
Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. (1987) (129)
Ensuring quality cancer care (2012) (129)
Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer (2000) (128)
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. (2013) (127)
Carcinoma of the Male Breast (1992) (127)
Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. (2011) (127)
Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. (2001) (127)
Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. (1986) (125)
Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. (1996) (124)
Fadrozole HCL (CGS‐16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trials (1996) (120)
Trends for inflammatory breast cancer: is survival improving? (2007) (120)
Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. (2005) (118)
Prognostic significance of phosphorylated P38 mitogen‐activated protein kinase and HER‐2 expression in lymph node‐positive breast carcinoma (2004) (118)
Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy (1986) (117)
Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. (2014) (117)
Evolving novel anti-HER2 strategies. (2009) (117)
Feasibility of Breast Preservation in the Treatment of Occult Primary Carcinoma Presenting With Axillary Metastases (2001) (115)
Inflammatory breast cancer and body mass index. (1998) (112)
Role of adjuvant chemotherapy in male breast cancer (1989) (112)
Efficacy of Anastrozole in Male Breast Cancer (2002) (111)
Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. (2001) (108)
Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients (1990) (104)
Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. (2004) (103)
Factors predicting long‐term survival for metastatic breast cancer patients treated with high‐dose chemotherapy and bone marrow support (1994) (103)
Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. (2005) (102)
Fulvestrant versus anastrazole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials (2004) (101)
Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. (2010) (96)
Pulmonary toxicity of mitomycin (1980) (96)
Update on endocrine therapy for breast cancer. (1998) (95)
Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. (2001) (95)
Endocrine therapy in the treatment of metastatic breast cancer. (2001) (94)
MANAGEMENT OF BREAST CANCER DURING PREGNANCY USING A STANDARDIZED PROTOCOL (1999) (93)
Complete remissions in metastatic breast cancer treated with combination drug therapy. (1979) (93)
Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. (2002) (92)
Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. (2011) (92)
Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. (2003) (91)
Accuracy of the Combination of Mammography and Sonography in Predicting Tumor Response in Breast Cancer Patients After Neoadjuvant Chemotherapy (2006) (91)
A prospective trial of preoperative chemotherapy in resectable breast cancer: Predictors of breast-conservation therapy feasibility (2002) (89)
Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. (2003) (89)
Preoperative chemotherapy treatment of breast cancer—A review (2007) (85)
Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma (1997) (85)
Ten‐Year Results of FAC Adjuvant Chemotherapy Trial in Breast Cancer (1989) (85)
Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. (1981) (84)
Recent advances in the treatment of breast cancer. (1991) (84)
Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification. (1989) (82)
Management of locoregional recurrent breast cancer (1986) (81)
Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. (1999) (81)
Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. (2003) (80)
Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. (2009) (79)
Current status of adjuvant systemic therapy for primary breast cancer: Progress and controversy (1995) (78)
Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. (1998) (78)
Pituitary‐ovarian function in breast cancer patients on adjuvant chemoimmunotherapy (1978) (78)
Management of inflammatory carcinoma of the breast: A combined modality approach (1985) (76)
Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. (2001) (76)
Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. (2000) (76)
Impact of multicentricity on clinical outcome in patients with T1-2, N0-1, M0 breast cancer (2007) (75)
Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. (1998) (75)
Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette‐Guerin and with or without irradiation in operable breast cancer a prospective randomized trial (1984) (75)
Women age < or = 35 years with primary breast carcinoma: disease features at presentation. (2005) (75)
Central nervous system metastases in patients with high‐risk breast carcinoma after multimodality treatment (2004) (74)
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. (2007) (74)
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. (2010) (73)
A review of adjuvant hormonal therapy in breast cancer. (2004) (73)
Paclitaxel in the multimodality treatment for inflammatory breast carcinoma (2001) (73)
Prognostic Value of a Combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and Comparison with the GHI Recurrence Score – Results from TransATAC. (2009) (73)
A Retrospective Study of First Indicators of Breast Cancer Recurrence (2000) (72)
Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer (1982) (71)
Combination chemoimmunotherapy of metastatic breast cancer with 5‐fluorouracil, adriamycin, cyclophosphamide, and BCG (1979) (70)
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. (2013) (69)
Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. (2003) (68)
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) Trial in Postmenopausal Women with Early Breast Cancer – Updated Efficacy Results Based on a Median Follow-up of 47 Months (2003) (68)
Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer (1978) (68)
T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. (2004) (68)
Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. (1983) (68)
Management of breast cancer patients failing adjuvant chemotherapy with adriamycin‐containing regimens (1981) (66)
Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Comparison of consecutive series of patients in 1950s, 1960s, and 1970s (1985) (66)
Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin‐containing adjuvant therapy (1992) (66)
Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up. (2000) (65)
A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. (2010) (65)
A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. (2002) (65)
Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer (2002) (65)
Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. (2007) (65)
Disease‐free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy (2006) (64)
Correlation between HER‐2 expression and response to neoadjuvant chemotherapy with 5‐fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma (2003) (64)
Doxorubicin-Based Chemotherapy in Elderly Patients With Metastatic Breast Cancer: Tolerance and Outcome (1996) (63)
The sequential use of endocrine treatment for advanced breast cancer: where are we? (2012) (63)
Erratum: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials (Cancer (1998) 83 (1142-1152)) (1999) (63)
Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients. (2004) (63)
Inflammatory Breast Cancer Survival: The Role of Obesity and Menopausal Status at Diagnosis (2000) (62)
Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. (2003) (62)
Multimodal treatment for inflammatory breast cancer. (1989) (62)
The feasibility of minimally invasive surgery for Stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy (2000) (61)
Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial. (2011) (61)
Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin (2007) (61)
Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. (2002) (61)
Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer. (1978) (61)
The order of administration of chemotherapy and radiation and its effect on the local control of operable breast cancer (1993) (61)
Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer? (1990) (61)
Tamoxifen‐induced hypercalcemia in breast cancer (1981) (60)
Management of inflammatory carcinoma of breast with combined modality approach—an update (1981) (60)
Combined‐modality treatment for isolated recurrences of breast carcinoma (2005) (59)
Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast (2011) (59)
Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. (1996) (58)
Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. (1990) (58)
p53 Expression as a Prognostic Marker in Inflammatory Breast Cancer (2004) (58)
Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. (1994) (57)
The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. (1993) (56)
Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen (1982) (56)
Estrogen receptor: a prognostic factor in breast cancer. (1981) (56)
Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy. (2003) (55)
Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience. (2002) (54)
A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. (1990) (53)
Adriamycin and mitomycin C: possible synergistic cardiotoxicity. (1978) (53)
Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel. (2009) (52)
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. (2008) (52)
Clinical features of joint symptoms observed in the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. (2006) (51)
The safety of breast‐conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy (2006) (51)
Classification of Ipsilateral Breast Tumor Recurrences After Breast Conservation Therapy Can Predict Patient Prognosis and Facilitate Treatment Planning (2011) (51)
Locally advanced noninflammatory breast cancer. (1996) (51)
Hormonal Therapy for Metastatic Male Breast Cancer (1983) (50)
Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer (2008) (49)
Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience (1999) (49)
Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer. (2001) (49)
Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED) (1979) (49)
Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): Initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease. (2004) (49)
Recent developments in breast cancer therapy. (1999) (48)
Fluorouracil, Doxorubicin, and Cyclophosphamide Followed by Tamoxifen as Adjuvant Treatment for Patients with Stage IV Breast Cancer with No Evidence of Disease (2002) (48)
The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy. (2000) (48)
Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. (1979) (48)
Primary inflammatory carcinoma of the breast: retrospective review of mammographic findings. (2000) (47)
Locally Advanced Breast Cancer: A Review Including the M.D. Anderson Experience (1991) (46)
A unified definition of clinical anthracycline resistance breast cancer (2000) (46)
Kinetics of serum HER‐2/neu changes in patients with HER‐2‐positive primary breast cancer after initiation of primary chemotherapy (2007) (46)
High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study. (1987) (45)
Expression of erbB/HER receptors, heregulin and p38 in primary breast cancer using quantitative immunohistochemistry (2009) (45)
Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study. (1991) (45)
The prognostic significance of sialyl‐tn Antigen in women treated with breast carcinoma treated with adjuvant chemotherapy (1997) (45)
Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer (1998) (44)
Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. (1996) (44)
TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. (2013) (44)
A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. (1997) (44)
Breast cancer in men. (2018) (44)
Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma. (1989) (43)
Sequencing of chemotherapy and radiation in lymph node-negative breast cancer. (1999) (43)
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma (2004) (42)
The Impact of Hormone Receptor Status on the Clinical Efficacy of the New‐Generation Aromatase Inhibitors: A Review of Data from First‐Line Metastatic Disease Trials in Postmenopausal Women (2004) (41)
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline‐ and nonanthracycline‐based regimens for HER2‐positive breast cancer (2012) (41)
Colitis in patients with breast carcinoma treated with taxane‐based chemotherapy (2004) (41)
Five‐day continuous‐infusion vinblastine in the treatment of breast cancer (1985) (41)
Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers (2008) (39)
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group. (2004) (39)
Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. (2009) (39)
Combined-modality approach for patients with isolated recurrences of breast cancer (IV-NED). The M. D. Anderson experience (1994) (39)
Primary chemotherapy for early and advanced breast cancer. (1995) (39)
Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy (2000) (39)
Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. (2012) (39)
A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma (1985) (39)
Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. (2001) (39)
Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer. (1992) (38)
Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole (2015) (37)
Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426) (2016) (37)
Cranial nerve palsies in metastatic breast cancer due to osseous metastasis without intracranial involvement (2006) (36)
Risks and Benefits of Aromatase Inhibitors in Postmenopausal Breast Cancer (1999) (36)
Anastrozole as an Adjuvant Endocrine Treatment for Postmenopausal Patients with Breast Cancer: Emerging Data (2006) (36)
Primary Tumor Response to Induction Chemotherapy as a Predictor of Histological Status of Axillary Nodes in Operable Breast Cancer Patients (1999) (36)
Staging of breast cancer in the neoadjuvant setting. (2008) (36)
Electrocardiographic changes after adriamycin chemotherapy (1979) (36)
Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy. (1979) (35)
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer (2007) (35)
Predictive algorithms for adjuvant therapy: TransATAC (2011) (35)
Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer (1999) (35)
Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy. (1983) (35)
Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy. The University of Texas M.D. Anderson Cancer Center experience and review of the literature. (1998) (34)
Inflammatory carcinoma of the breast: results of a combined-modality approach — M. D. Anderson Cancer Center experience (1990) (34)
The natural history of breast carcinoma in patients with ≥ 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy (2005) (34)
Second Neoplasms After Adjuvant Chemotherapy for Operable Breast Cancer (1986) (34)
Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma (1979) (33)
Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. (1995) (33)
Capecitabine (Xeloda) in 162 patients with paclitaxel-pretreated mbc: updated results and analysis of dose modification (2001) (33)
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. (2011) (33)
Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion. (1981) (33)
Is breast cancer survival improving?: Trends in survival for patients with recurrent breast cancer diagnosed from 1974 through 2000 (2004) (33)
Randomized trial of high‐dose chemotherapy and autologous hematopoietic stem cell support for high‐risk primary breast carcinoma (2006) (32)
Are aromatase inhibitors superior to antiestrogens? (2005) (32)
Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. (2004) (32)
Mammographic Breast Density Response to Aromatase Inhibition (2013) (32)
Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer (2015) (31)
Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC). (2011) (31)
Fulvestrant: Pharmacologic Profile Versus Existing Endocrine Agents for the Treatment of Breast Cancer (2006) (31)
Measurement of estrogen and progesterone receptors in human breast tumors: enzyme immunoassay versus binding assay. (1990) (31)
TAS-108, a Novel Oral Steroidal Antiestrogenic Agent, Is a Pure Antagonist on Estrogen Receptor α and a Partial Agonist on Estrogen Receptor β with Low Uterotrophic Effect (2005) (30)
Efficacy of pre-operative Arimidex (anastrozole) compared with tamoxifen (PROACT) as neoadjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer (2004) (30)
What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis (2004) (30)
Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer (2006) (30)
Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer. (2004) (29)
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update. (2004) (29)
The effect of anastrozole (Arimidex™) on serum lipids — a randomized comparison of Anastrozole (AN) vs Tamoxifen (TAM) in Postmenopausal women with Advanced Breast Cancer (2001) (28)
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy (2015) (28)
Combined chemoimmunotherapy for advanced breast cancer. A comparison of BCG and levamisole (1979) (28)
Topoisomerase IIα Gene Amplification and Response to Anthracycline-Containing Adjuvant Chemotherapy in Breast Cancer (2006) (28)
Aromatase Inhibitors: Current Status (1995) (28)
Combined modality approach in breast cancer with isolated or multiple metastases (1984) (27)
Lack of association between amplification of her‐2 and response to preoperative taxanes in patients with breast carcinoma (2004) (27)
Alternating noncross‐resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER‐BCG for advanced breast carcinoma (1980) (27)
Mitomycin‐C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy (1978) (27)
Prognostic Implications of Pathological Lymph Node Status After Preoperative Chemotherapy for Operable T3N0M0 Breast Cancer (2000) (27)
Combination endocrine therapy in the management of breast cancer. (2001) (27)
Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs (1988) (26)
Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement (2017) (26)
Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy—results from the ACOSOG Z1041 (Alliance) trial (2017) (25)
Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. (1995) (25)
Novel Clinical Trial Designs for Treatment of Ductal Carcinoma In Situ of the Breast with Trastuzumab (Herceptin) (2007) (25)
Phase II study of vinorelbine administered by 96‐hour infusion in patients with advanced breast carcinoma (1999) (25)
Data from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trial (2004) (25)
What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis? (2004) (24)
Superior efficacy of letrozole versus tamoxifen as first-line therapy. (2002) (24)
Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer (2005) (24)
The management of locally advanced breast cancer: a combined modality approach. (1984) (24)
Anastrozole (Arimidex™) in clinical practice versus the old ‘gold standard’, tamoxifen (2002) (24)
Prognostic value of P53, MDM‐2, and MUC‐1 for patients with inflammatory breast carcinoma (2004) (24)
Hormonal therapy for metastatic male breast cancer. (1983) (23)
A summary of second-line randomized studies of aromatase inhibitors (2001) (23)
The current status of aromatase inhibitors in the management of breast cancer. (2003) (23)
Pigmentation of the tongue and mucous membranes associated with cancer chemotherapy. (1979) (23)
Metastatic Breast Carcinoma Mimicking an Acute Paronychia of the Great Toe: Case Report and Review of Subungual Metastases (1993) (23)
Role of aromatase inhibitors in advanced breast cancer. (1999) (23)
Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial. (2017) (23)
A randomized phase 2 trial comparing 3‐hour versus 96‐hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer (2010) (23)
Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. (2011) (23)
Results of adjuvant chemotherapy trials in breast cancer at M. D. Anderson Hospital and Tumor Institute. (1986) (23)
Trioxifene mesylate in the treatment of advanced breast cancer (1986) (23)
Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy (1980) (22)
Management of inflammatory breast cancer (2004) (22)
Combination chemoimmunotherapy of metastatic breast cancer with 5‐fluorouracil, adriamycin, cyclophosphamide, and BCG (1979) (22)
Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer. (1979) (22)
Paclitaxel: severe mucocutaneous toxicity in a patient with hyperbilirubinemia. (1996) (22)
Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. (1995) (22)
Impact of chemotherapy regimens prior to endocrine therapy (2006) (22)
‘Arimidex’ (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer-efficacy overview (2003) (22)
Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer. (1997) (22)
Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. (1979) (22)
Anastrozole: A Viewpoint by Aman U. Buzdar (2002) (21)
Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer. (1997) (21)
The Role of Serum CEA as a Prognostic Indicator in Stage II and III Breast Cancer Patients Treated With Adjuvant Chemotherapy (1989) (21)
Aromatase inhibitors in metastatic breast cancer. (1996) (21)
New Generation Aromatase Inhibitors – from the Advanced to the Adjuvant Setting (2002) (21)
A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma (1992) (21)
Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. (2003) (21)
Delphi‐panel analysis of appropriateness of high‐dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer (2000) (21)
Ftorafur, adriamycin, cyclophosphamide and bcg in the treatment of metastatic breast cancer (1979) (20)
Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial. (2003) (20)
Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast (2001) (20)
Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. (1999) (20)
Exemestane in advanced breast cancer (2000) (20)
Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer (1991) (19)
Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy (2000) (19)
Tumor‐associated fever in breast cancer (1984) (19)
Subclinical hepatic toxicity during combination chemotherapy for breast cancer. (1986) (19)
SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway (2017) (19)
ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer (1997) (19)
TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect. (2005) (19)
Spontaneous regression of breast carcinoma: Follow‐up report and literature review (1982) (19)
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer (1997) (19)
Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2‐positive breast cancer using an LC‐MALDI‐TOF/MS procedure (2010) (18)
Using Multiple Targeted Therapies in Oncology: Considerations for Use, and Progress to Date in Breast Cancer (2013) (18)
A Phase I and Pharmacokinetic Study of TAS-108 in Postmenopausal Female Patients with Locally Advanced, Locally Recurrent Inoperable, or Progressive Metastatic Breast Cancer (2004) (18)
The place of chemotherapy in the treatment of early breast cancer. (1998) (18)
Progress in inflammatory breast cancer: cause for cautious optimism. (1986) (18)
Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer (1985) (18)
Elliptinium acetate in metastatic breast cancer--a phase II study. (1990) (18)
Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen (1982) (18)
Prognostic value of prechemotherapy skin tests in patients with metastatic breast carcinoma (1981) (17)
Aromatase inhibitors: changing the face of endocrine therapy for breast cancer. (2005) (17)
Recent advances in aromatase inhibitor therapy for breast cancer. (2002) (17)
Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial (2019) (17)
A phase II study of peptichemio in advanced breast cancer (1980) (17)
10-year analysis of the ATAC trial: wrong conclusion? – Authors' reply (2011) (17)
Cyclophosphamide-induced urticaria. Occurrence in a patient with no cross-sensitivity to chlorambucil. (1978) (17)
TAS-108: a novel steroidal antiestrogen. (2005) (17)
How rapidly do oncologists respond to clinical trial data? (2005) (16)
Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer. (2008) (16)
Phase II study of deoxyspergualin in metastatic breast cancer (2004) (16)
Normal cardiac biopsy results following co-administration of doxorubicin (A), Cyclophosphamide (C) and trastuzumab (H) to women with HER2 positive metastatic breast cancer (2004) (16)
Adjuvant chemotherapy with fluorouracil, doxorubicin and cyclophosphamide (FAC) in stage II or III breast cancer; 5-year results (1981) (16)
Aminoglutethimide after tamoxifen therapy in advanced breast cancer: M. D. Anderson Hospital experience. (1982) (15)
Current status of endocrine treatment of carcinoma of the breast. (1990) (15)
Adriamycin and 1‐(2‐Chlorethyl)‐3‐Cyclohexyl‐1‐Nitrosourea (CCNU) in the treatment of metastatic breast cancer (1978) (15)
Chemotherapeutic approaches to advanced breast cancer. (1988) (15)
Use of Taxol (paclitaxel) in breast cancer. (1994) (15)
ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T → FEC+T) in HER2+ operable breast cancer. (2013) (15)
Aggressive therapy for locoregional recurrence after mastectomy in stage II and III breast cancer patients (2006) (15)
Preliminary study of cardiac accumulation of F-18 fluorotamoxifen in patients with breast cancer. (1997) (15)
Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy (1985) (15)
A phase II study of tipifarnib and gemcitabine in metastatic breast cancer (2018) (15)
Percutaneous Hepatic Arterial Infusion of Cisplatin‐Vinblastine for Refractory Breast Carcinoma Metastatic to the Liver (1988) (15)
Combination chemotherapy for breast cancer metastatic to bone marrow (1981) (15)
Phase II study of taxotere in refractory metastatic breast cancer (RMBC) (1993) (15)
Are differences in the available aromatase inhibitors and inactivators significant? (2001) (15)
Anastrozole (Arimidex ™) – an aromatase inhibitor for the adjuvant setting? (2001) (15)
Recent advances in adjuvant therapy of breast cancer. (1999) (14)
Hematologic adverse effects of aminoglutethimide. (1984) (14)
Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer a prospective, randomized trial (1987) (14)
Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger (2008) (14)
The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer. (1997) (14)
Hormonal therapy with tamoxifen in male breast cancer. (1979) (14)
Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer. (1994) (13)
Response to Induction Chemotherapy in Black and White Patients with Locally Advanced Breast Cancer (2000) (13)
Evaluation of patients after primary therapy for early breast cancer (1993) (13)
Complications associated with indwelling catheters. (1992) (13)
Lorazepam‐Enhancement of the Antiemetic Efficacy of Dexamethasone and Promethazine: A Placebo‐Controlled Study (1994) (13)
Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study (2013) (13)
Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer. (1979) (13)
Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511) (2016) (13)
Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control (2011) (13)
Tamoxifen's clinical applications: old and new. (2000) (13)
Women age ≤ 35 years with primary breast carcinoma (2005) (13)
Making genuine progress against metastatic breast cancer. (2012) (12)
Bilateral Primary Breast Cancer in Patients Treated with Adjuvant Therapy (1988) (12)
Leukocyte interferon (IF) induced tumor regression in patients (pts) with breast cancer and B cell neoplasms (1979) (12)
Spontaneous regression of breast carcinoma. (1978) (12)
Current Status of Adjuvant Therapy of Early Breast Cancer (1991) (12)
Endobronchial metastases in breast carcinoma. (1978) (12)
Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy (1987) (12)
Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer. (2012) (12)
Inflammatory breast carcinoma. (1986) (12)
A Phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma (2003) (12)
Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guérin. (1978) (12)
Hormone receptors in breast cancer and response to chemotherapy. (1979) (12)
Sequential cyclic combined hormonal therapy for metastatic breast cancer (1989) (11)
FAC + BCG as adjuvant therapy in breast cancer: an 8-year update. (1984) (11)
Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer. (2006) (11)
Anastrozole: a new selective nonsteroidal aromatase inhibitor. (1997) (11)
Efficacy of Anastrozole in a Consecutive Series of Advanced Breast Cancer Patients Treated with Multiple Prior Chemotherapies and Endocrine Agents: M. D. Anderson Cancer Center Experience (1999) (11)
Cost-effectiveness implications of increased survival with anastrozole in the treatment of advanced breast cancer (1999) (11)
Impact of patient characteristics on treatment outcome: anthracycline resistance. (1997) (11)
Phase I study of vinorelbine and paclitaxel by 3‐hour simultaneous infusion with and without granulocyte colony‐stimulating factor support in metastatic breast carcinoma (2001) (11)
Aminoglutethimide-induced hematologic toxicity: worldwide experience. (1985) (11)
Noninvasive cardiac evaluation of patients receiving adriamycin‐containing adjuvant chemotherapy (FAC) for stage II or III breast cancer (1983) (11)
Peptichemio versus melphalan (L‐PAM) in advanced breast cancer (1982) (10)
Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer (2004) (10)
Sixteen-week, dose-intense chemotherapy in adjuvant treatment of breast cancer. (1990) (10)
Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer. (1997) (10)
An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer. (2000) (10)
Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action (2020) (10)
An exploration of relapse data by hazard rate as a means of developing biological insights into the natural history and treatment of breast cancer: Data from the ’Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial and the Milan Institute database (2005) (10)
Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. (2015) (10)
Osteoblastic metastatic disease as a therapeutic response to adjuvant chemotherapy in breast cancer (1983) (10)
Endocrine and targeted manipulation of breast cancer: Summary statement for the Sixth Cambridge Conference (2008) (10)
Present Status of Anthracyclines in the Adjuvant Treatment of Breast Cancer (2012) (10)
Azathioprine and breast carcinoma. (1978) (10)
Aromatase inhibitors in breast cancer therapy. (2003) (10)
Abstract P5-10-02: Clinical Outcome of Two Sequences of Administering Paclitaxel (P) and Anthracyclines (A) as Primary Systemic Therapy (PST) and Adjuvant Chemotherapy (ACT) in Breast Cancer (BC) Patients: A Retrospective Analysis from the M. D. Anderson Cancer Center (MDACC) (2010) (9)
Is Anastrozole Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer?: In Reply (2001) (9)
Impact of adjuvant chemotherapy prior to endocrine therapy: 68 month results from the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial (2005) (9)
Pregnancy and breast cancer: clinical and legal issues. (1992) (9)
A comparative study of PALA, PALA plus 5‐FU, and 5‐FU in advanced breast cancer (1985) (9)
Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by deoxyspergualin: a phase I study. (1994) (9)
High-dose chemotherapy with autologous stem cell support in patients with breast cancer. (1998) (9)
Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer. (2008) (9)
Acute superior vena caval thrombosis after central venous catheter removal: successful treatment with thrombolytic therapy. (1990) (9)
Phase II study of iproplatin in metastatic breast carcinoma. (1987) (9)
Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. (1984) (9)
Adjuvant chemotherapy for high-risk operable breast cancer. (2007) (9)
104. Randomized phase III study of the new selective aromatase inhibitor arimidex (A) (ZD1033) versus megestrol acetate (MA) in the treatment of postmenopausal women with advanced breast cancer (1995) (9)
Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma. (1978) (9)
Phase I trail of droloxifene in patients with metastatic breast cancer (2004) (9)
Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine. (1980) (9)
Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer (1979) (9)
Massive osteolysis of the right clavicle developing after radiation therapy. (1988) (9)
Dietary modification and risk of breast cancer. (2006) (8)
Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience (1999) (8)
Arzoxifene: the evidence for its development in the management of breast cancer (2007) (8)
Anastrozole: a new addition to the armamentarium against advanced breast cancer. (1998) (8)
Adjuvant chemoimmunotherapy of stage IV (NED) breast cancer (1977) (8)
Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma. (1979) (8)
Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual (2016) (8)
S4-7: Results of a Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Adjuvant Lapatinib in Women with Early-Stage ErbB2-Overexpressing Breast Cancer. (2011) (8)
Combination chemoimmunotherapy with FAC‐BCG for metastatic breast cancer: The impact of CMF maintenance chemotherapy (1981) (8)
Normal cardiac biopsy results following co-administration of doxorubicin (A), Cyclophosphamide (C) and trastuzumab (H) to women with HER2 positive metastatic breast cancer. (2004) (7)
Usage of erythropoiesis‐stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia (2011) (7)
Cancer Therapy : Clinical Loss of HER 2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes (2009) (7)
Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome‐Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2 (2019) (7)
Adjuvant use of anastrozole in breast cancer. (2004) (7)
Evaluation of polyinosinic-polycytidylic and poly-L-lysine in metastatic breast cancer. (1986) (7)
Endobronchial metastasis from cancer of the breast. (1978) (7)
Phase I–II Vinorelbine (Navelbine®) by Continuous Infusion in Patients with Metastatic Breast Cancer: Cumulative Toxicities Limit Dose Escalation (2001) (7)
Second-line chemotherapy for metastatic breast cancer including quality of life issues (1996) (7)
Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer (1988) (7)
Abstract P5-13-03: The Influences of Co-Morbidities and Age on Risk of Death without Recurrence: A Retrospective Analysis of the ATAC Trial (2010) (7)
Radiation treatment improves local-regional control and survival in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy (2003) (7)
Phase I trial of droloxifene in patients with metastatic breast cancer. (1994) (7)
Optimum use of aromatase inhibitors in the adjuvant treatment of early breast cancer. (2005) (7)
Letrozole compared with tamoxifen as initial adjuvant therapy for breast cancer. (2007) (7)
Use of prognostic factors in analysis of historical control studies. (1980) (7)
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. (2005) (7)
Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone. (1984) (7)
ADJUVANT ENDOCRINE THERAPY FOR POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER — (7)
Cisplatin in Combination with Continuous Infusion Vinblastine for Refractory Breast Cancer (1988) (6)
Role of anastrozole in adjuvant therapy for postmenopausal patients. (2003) (6)
Safety, tolerability, and pharmacokinetics of TAS‐108 in normal healthy post‐menopausal female subjects: a phase I study on single oral dose (2005) (6)
M.D.Anderson cancer care series (2001) (6)
Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. (2003) (6)
Longitudinal nail banding associated with breast carcinoma unrelated to chemotherapy. (1978) (6)
Anastrozole (Arimidex), a new aromatase inhibitor for advanced breast cancer: mechanism of action and role in management. (1998) (6)
Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. (2003) (6)
Clinical experience with epothilones in patients with breast cancer. (2008) (6)
A Roundtable Discussion of Aromatase Inhibitors as Therapy for Breast Cancer (2003) (6)
A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer (1986) (6)
Dose intensity studies in breast cancer--autologous bone marrow transplantation. (1990) (6)
Evidence for change in prognostic stratification of breast tumor subtypes. (2010) (6)
Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer (1983) (6)
Hormonal Therapy in Early and Advanced Breast Cancer (2004) (5)
Trilostane with hydrocortisone in treatment of metastatic breast cancer (1989) (5)
Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer. (2006) (5)
Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement. (2001) (5)
The effect of different sequencing regimens of taxanes and anthracyclines in the primary systemic treatment (PST) of breast cancer (BC) patients (pts): M. D. Anderson Cancer Center retrospective analysis. (2010) (5)
Pirarubicin in Combination Chemotherapy for Metastatic Breast Cancer (1990) (5)
ACOSOG Z1041 (Alliance): Cardiac events (CE) among those receiving neoadjuvant anthracyclines (A) and taxanes with trastuzumab (T) for HER2+ breast cancer. (2013) (5)
Randomized double‐blind phase 2 trial of 3 doses of TAS‐108 in patients with advanced or metastatic postmenopausal breast cancer (2012) (5)
Effect of dose modification on the efficacy of capecitabine: Data from six randomized, phase III trials in patients with colorectal or breast cancer. (2011) (5)
Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: Conference Summary Statement (2006) (5)
Viral-induced remission in chronic lymphocytic leukemia? (1979) (5)
High-dose 1-beta-D-arabinofuranosylcytosine in advanced breast cancer. (1985) (5)
Inflammatory Breast Cancer: Clinical Features and the Role of Multimodality Therapy (1996) (5)
Is overall survival an appropriate endpoint in early breast cancer studies? Data from the ATAC study at 100-month median follow-up (2008) (5)
Aromatase inhibitors alone or in sequence with tamoxifen - Clinical Evaluation of the BIG 1-98 trial (2010) (5)
Clinical trial of plasma perfusion over immobilized staphylococcal protein A in metastatic breast cancer. (1987) (5)
Letrozole or tamoxifen in early breast cancer. (2006) (5)
Recent advances in the hormonal treatment of breast cancer. (2008) (5)
Significantly improved survival with 'arimldex' (anastrozole (A)) compared with megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC): Updated results of two randomised trials (1997) (5)
Complete Estrogen Blockade for the Treatment of Metastatic and Early Stage Breast Cancer (2000) (5)
Significance of drug dose, timing and radiotherapy in adjuvant therapy of breast cancer. (1984) (5)
Immune‐complex glomerulonephritis secondary to nonspecific immunotherapy (1980) (5)
Letrozole: which dose to be used? (2000) (5)
Chemo immunotherapy of advanced breast cancer with BCG. (1977) (5)
Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. (2000) (4)
Articles: Fulvestrant - A novel estrogen receptor antagonist for the treatment of advanced breast cancer. (2008) (4)
Adjuvant chemotherapy for breast cancer with fluorouracil, adriamycin, cyclophosphamide (FAC) with or without BCG and with or without post-operative irradiation (XRT). A prospective randomized study (1982) (4)
Twelve-year follow-up of a randomized trial of high-dose chemotherapy (HDC) and autologous hematopoietic stem cell support (ASCS) for high-risk primary breast carcinoma (2005) (4)
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. (2016) (4)
Primary chemotherapy for breast cancer — MD Anderson experience (1991) (4)
Eradication of Axillary Lymph Node Metastases Occurs in 74% of Patients Receiving Neoadjuvant Chemotherapy with Concurrent Trastuzumab for HER2 Positive Breast Cancer. (2009) (4)
Letrozole in breast cancer. (2004) (4)
Erratum: Buzdar AU, Guastalla J‐P, Nabholtz J‐M, et al. Impact of chemotherapy regimens prior to endocrine therapy: results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial. Cancer. 2006; 107(3):472–80. (2006) (4)
Fast facts: Breast cancer (2003) (4)
Post-mastectomy angiosarcoma: case report and review of the literature. (1984) (4)
Invasive lobular carcinoma (ILC) "classic type": Distinct clinical features. (2004) (4)
Anastrozole for breast cancer: recent advances and ongoing challenges (2006) (4)
Regional consolidative therapy following systemic chemotherapy in metastatic breast cancer (1982) (4)
Anastrozole (2010) (4)
Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio (1984) (4)
Clinically-relevant pneumonitis is not increased in breast cancer patients treated with sequential paclitaxel and radiation (2003) (4)
Update on Adjuvant Chemotherapy for Early Breast Cancer (2017) (4)
Short-Term Biomarker Modulation Prevention Study of Anastrozole in Women at Increased Risk for Second Primary Breast Cancer (2011) (4)
Benign versus malignant hepatic lesions. A diagnostic dilemma with breast cancer patients (1983) (4)
Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. (2022) (4)
Update on the management of inflammatory breast cancer. (2006) (3)
Value of adjuvant radiation therapy in breast cancer patients with one to three positive lymph nodes undergoing a modified radical mastectomy and systemic therapy. (2009) (3)
Hormonal aspects of breast cancer: Introduction (2000) (3)
Pattern of chemotherapy use at end of life (EOL) in patients with solid tumors (ST). (2013) (3)
Reutilization of doxorubicin in patients with progressive metastatic breast cancer (1989) (3)
351 Two randomised trials establishing efficacy and tolerability of arimidex (ZD1033) in the treatment of postmenopausal women with advanced breast cancer (PABC) (1995) (3)
Genes associated with serum estrone, estrone conjugates, and androstenedione concentrations in postmenopausal women with estrogen receptor-positive breast cancer. (2014) (3)
CARCINOMA OF THE MALE BREAST. RESPONSE (1993) (3)
Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, and prednisone (1984) (3)
Rubidazone in metastatic breast cancer. (1979) (3)
Radiation-induced breast cancer. (1984) (3)
Prospective randomized trial evaluating weekly paclitaxel (WP) versus docetaxel in combination with capecitabine (DC) in operable breast cancer. (2009) (3)
Characterization of bone mineral density (BMD) at the time of diagnosis in postmenopausal patients with operable breast cancer: Association with clinical-pathological findings (2005) (3)
Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancer. (1982) (3)
Ethical Considerations in Human Subjects Research (2017) (3)
Management of locally advanced breast cancer. (1988) (3)
Breast Conservation after Tumor Downstaging with Induction Chemotherapy (1999) (3)
Efficacy of tamoxifen (TAM) following Anastrozole (AN) as first-line treatment for Advanced Breast Cancer (ABC) in Postmenopausal (PM) Patients (PTS) (2001) (3)
What is Best for the Patient? A United States View (1988) (3)
Factors related to end-of-life (EOL) chemotherapy in solid tumor (ST) patients. (2013) (3)
Her2-Neu overexpression does not increase the risk of local-regional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiation (2003) (3)
Sequential paclitaxel reduces recurrence and mortality in women with early breast cancer. (2003) (2)
Pharmacogenomic analysis of HER2 amplified breast cancer treated with preoperative trastuzumab and paclitaxel, 5-fluorouracil, epirubicin, cyclophosphamide (T/FEC) chemotherapy. (2006) (2)
Cerebromedullospinal disconnection after intraventricular methotrexate. (1978) (2)
Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer (2003) (2)
Anti-angiogenic therapies in metastatic breast cancer-an unfulfilled dream. (2011) (2)
Age, race, BMI, and pathologic complete response following neoadjuvant chemotherapy: An analysis of four alliance clinical trials. (2015) (2)
Adjuvant lapatinib in women with early-stage HER2-positive breast cancer (HER2+ BC): Analysis of the hormone receptor-negative subgroup of the intent-to-treat (ITT) population of the TEACH trial. (2012) (2)
Radiotherapy enhances the toxicity of aminoglutethimide. (1990) (2)
Meta-analysis: Selective estrogen-receptor modulators reduce breast cancer incidence (2013) (2)
Long-term outcome of patients with complete eradication of cytologically proven axillary node metastases after primary chemotherapy: The University of Texas M. D. Anderson Cancer Center experience (2004) (2)
Leukocyte interferon induces tumor regression in patients with breast cancer and B cell neoplasms (1979) (2)
Combination endocrine treatments unproven in breast cancer. (2013) (2)
Medical oncology: Endocrine-therapy-related symptoms and breast cancer (2009) (2)
Breast cancer. (1999) (2)
A comparative randomized trial of doxorubicin and cyclophosphamide in combination with fluorouracil (FAC) or etoposide (EAC) in metastatic breast cancer (1988) (2)
Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer (1979) (2)
Endocrine therapy of metastatic breast cancer (2000) (1)
Abstract PD1-04: CSMD1 SNPs selectively affect anastrozole response in postmenopausal breast cancer patients (2017) (1)
P2-12-09: Prediction of Residual Risk of Recurrence after 5 Years of Follow-Up by Clinicopathologic Variables and 4 IHC Markers: A TransATAC Study. (2011) (1)
Primary chemotherapy for breast cancer : response to preoperative chemotherapy as prognostic factor (1994) (1)
Validation of a novel staging system for breast cancer patients treated with neoadjuvant chemotherapy. (2016) (1)
Body mass index and response to neoadjuvant chemotherapy in breast cancer patients (2007) (1)
Prognostic value of residual cancer burden after neoadjuvant taxane-anthracycline chemotherapy in phenotypic subsets of breast cancer (2008) (1)
Evaluation of serum profiles changes after neoadjuvant chemotherapy for breast cancer using MALDI-TOF/MS procedure. (2009) (1)
High dose oral medroxyprogesterone acetate (MPA) for the treatment of metastatic breast cancer (MBC) (1982) (1)
Knowledge acquisition from historical data: application to breast cancer patients. (1980) (1)
Correlation between response to neoadjuvant chemotherapy (NACT) with single agent taxanes and HER-2 gene amplification in patients with breast carcinoma (2004) (1)
Phase II study of peplomycin in advanced breast carcinoma. (1987) (1)
Peptichemio in treatment of advanced refractory breast cancer - A phase II study (1979) (1)
The role of aromatase inhibitors as adjuvant therapy in early breast cancer (2004) (1)
Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancer (1982) (1)
Phase I study of the novel oral steroidal antiestrogenic agent TAS-108, ascending single dose, safety, tolerance, and pharmacokinetic parameters in healthy postmenopausal women (2001) (1)
DISTRIBUTION OF (7α)-21-[4-[(DIETHYLAMINO) METHYL]-2-METHOXYPHENOXY]-7-METHYL-19-NORPREGNA-1,3,5(10)-TRIEN-3-OL-20-[14C]2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE ([14C]TAS-108) AND ITS METABOLITES AFTER SINGLE ORAL ADMINISTRATION TO RATS BEARING 7,12-DIMETHYLBENZ(α)ANTHRACENE-INDUCED MAMMARY TUMOR (2006) (1)
1 Progestins in Cancer Treatment (1988) (1)
The third-generation aromatase inhibitors: a clinical overview (2008) (1)
Locoregional R ecurrence P atterns A fter M astectomy a nd Doxorubicin-Base d C hemotherapy: I mplications f or Postoperative I rradiation (2000) (1)
St Gallen guidelines: aromatase inhibitors recommended by name for adjuvant therapy. (2006) (1)
Current status of adjuvant therapy of breast cancer (1996) (1)
AMSA and peptichemio in the treatment of advanced metastatic breast cancer: A phase II study (1982) (1)
An intensive new adjuvant chemoimmunotherapy program containing 5 fluorouracil (5 FU), adriamycin (AD), cyclophosphamide (CYT), and BCG (FAC BCG) for operable breast cancer (1977) (1)
Critique of survival update analysis from two phase III anastrozole clinical trials. (1999) (1)
Effect of timing of initiation of adjuvant chemotherapy on disease-free (D-F) interval in operable breast cancer (1981) (1)
Prolongation of disease-free and overall survival with the adjuvant FAC-BCG in stage II, III breast cancer (1979) (1)
Adjuvant chemotherapy in high-risk breast cancer patients with ten or more positive lymph nodes. (1992) (1)
P2-12-01: Immunohistochemical (IHC) BAG1 Expression Improves the Estimation of Residual Risk (RR) by IHC4 in Postmenopausal Patients Treated with Anastrozole or Tamoxifen: A TransATAC Study. (2011) (1)
Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer. (2012) (1)
Phase I–II study of high-dose etoposide in patients with refractory breast cancer (1991) (1)
Long-term efficacy and late sequelae of Doxorubicin containing adjuvant therapy for breast cancer : MD Anderson Cancer Center studies (1994) (1)
U.S. experience in neoadjuvant therapy of operable breast cancer (2004) (1)
Chemotherapy with mitoxantrone in combination with continuous infusion vinblastine for metastatic breast cancer (1987) (1)
Current Development in Hormonal Therapy of Breast Cancer (2004) (1)
Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate (1984) (1)
Endocrine Therapies in Breast Cancer (2007) (1)
Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone. (1984) (1)
Abstract P2-09-03: Long-term comparison of anastrozole versus tamoxifen: Results from LATTE/ATAC (2017) (1)
Multidisciplinary Care of the Breast Cancer Patient: Overview and Implementation (2001) (1)
Body mass index (BMI) is a predictor for response to neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger (2004) (1)
High-dose chemotherapy intensification with bone marrow support for hormone receptor negative or hormonal refractory relapsing breast cancer (1989) (1)
Induction chemotherapy of breast cancer. (1985) (1)
The current state of preoperative (Neoadjuvant) hormonal therapy for breast cancer (2004) (1)
Adjuvant therapy of breast cancer. (1984) (1)
Capecitabine in operable triple receptor-negative breast cancer: A subgroup analysis of a randomized phase III trial. (2011) (1)
Defining the competing risk of local-regional and distant recurrence in 1,256 patients treated with mastectomy and doxorubicin-based adjuvant chemotherapy. (2004) (1)
Combining endocrine and chemotherapy — any true benefits? (1984) (1)
Author reply (2002) (1)
Multidisciplinary Care of Breast Cancer Patients: Overview and Implementation (2008) (0)
Future Perspectives in the Clinical Development of Aromatase Inhibitors (2003) (0)
Trilostane, an effective signal transduction inhibitor for advanced ER+ve and ER-ve post-menopausal breast cancer (2004) (0)
Adjuvant chemoimmunotherapy of operable breast cancer - Update report (1978) (0)
Drug-associated cardiotoxicity. (1979) (0)
Abstract P6-11-02: Final Analysis of NO16853, a Randomized Phase II Non-Inferiority Study of Two Different Doses of Capecitabine in Combination with Docetaxel for Locally Advanced/Metastatic Breast Cancer (LA/MBC) (2010) (0)
Brachial plexopathy and porencephaly in a patient with breast cancer (1994) (0)
A PHASE I-II evaluation of trioxifene mesylate in the treatment of advanced breast cancer (1981) (0)
The impact of hormone receptor status on pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy with or without trastuzumab (2007) (0)
Role of routine postoperative radiotherapy and nonspecific immunotherapy with BCG in combination with adjuvant chemotherapy in operable breast cancer a prospective randomized trial (1981) (0)
Conclusion: Breast cancer is similar in men and women; how- ever, breast cancer in men is more frequently hormone receptor positive and may be more sensitive to hormonal therapy. (2002) (0)
Prospective E valuation o f P aclitaxel V ersus C ombination Chemotherapy W ith F luorouracil, D oxorubicin, and C yclophosphamide a s N eoadjuvant T herapy i n P atients With O perable B reast C ancer (1999) (0)
Endocrine Therapy for Hormone Receptor‐Positive Breast Cancer (2019) (0)
Chemotherapy of Metastatic Breast Cancer TAXANES : DRUGS OF THE 1990 S The introduction of paclitaxel ( Taxol ® (2001) (0)
Anastrozole Is Super ior to Tamoxi fen as Firs t-Line Therapy for Advanced Breast Cancer in Postmenopausal Women : Resul ts of a North American Mult icenter Randomized Tria l (0)
Distribution of (7alpha)-21-[4-[(diethylamino) methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol-20-[14C]2-hydroxy-1,2,3-propanetricarboxylate ([14C]TAS-108) and its metabolites after single oral administration to rats bearing 7,12-dimethylbenz(alpha)anthracene-induced mammary tum (2006) (0)
In reply [4] (2006) (0)
Paclitaxel in Early Breast Cancer (2012) (0)
Investigating the disparate enrollment of older adults on phase I clinical trials: Evolving participation patterns of patients 65 years and older w advanced cancer on phase I trials. (2020) (0)
0181 PROACT: A randomised study comparing anastrozole with tamoxifen as neoadjuvant and adjuvant treatment in postmenopausal women with locally advanced breast cancer - a Japanese subgroup analysis (2009) (0)
Remission and survival data of metastatic breast cancer patients (PTS) achieving complete remission (CR) with combination chemoimmunotherapy (CI) (1978) (0)
Breast cancer. (1984) (0)
Predictors of systemic recurrence and impact of local failure among early stage breast cancer patients treated with breast conserving therapy (2001) (0)
Paclitaxel-Based Chemotherapy and Radiotherapy in Breast Cancer Patients (2004) (0)
Trastuzumab: Further Considerations (2006) (0)
Aromatase Inhibitors (2002) (0)
Abstract P2-09-02: Validation of a Novel Staging System for Disease-Specific Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy (2010) (0)
Preoperative (neoadjuvant) therapy in breast cancer : Current status and future prospectives (2006) (0)
Evaluation of Changes in Plasma Protein Profiles during Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Using MALDI-TOF/MS Procedure. (2009) (0)
Current developments in hormonal therapy of breast cancer. (2004) (0)
Adjuvant use of anastrozole in breast cancer. Authors' reply (2004) (0)
Long-term outcome of patients with complete eradication of cytologically proven axillary node metastases after primary chemotherapy: The University of Texas M. D. Anderson Cancer Center experience. (2004) (0)
Phase I I, R andomized, D ouble-Blind S tudy o f T wo D ose L evels of A rzoxifene i n P atients W ith L ocally A dvanced o r M etastatic Breast C ancer (2003) (0)
Commentary (Buzdar): Optimizing Adjuvant Chemotherapy in Early-Stage Breast Cancer (2005) (0)
AIs vs Tamoxifen: Results of EBCTG Meta-Analyses (2009) (0)
Clinical Outcomes in Two Different Cohorts of Patients with Inflammatory Breast Cancer (IBC) Treated at the MD Anderson Cancer Center: The Experience of the Morgan Welch IBC Research Program and Clinic. (2009) (0)
10-year analysis of the ATAC trial: wrong conclusion? Reply (2011) (0)
Body mass index (BMI) is a predictor for response to neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. (2004) (0)
More Notable Trials From SABCS 2008 (2009) (0)
Sequential Magnetic Resonance and Response of Breast Cancer to Neoadjuvant Therapy (2003) (0)
The Goss/Tye Article Reviewed (1997) (0)
Peplomycin in treatment of advanced metastatic breast cancer-A phase II study (1985) (0)
Commentary (Buzdar): Nonsteroidal and Steroidal Aromatase Inhibitors in Breast Cancer (2001) (0)
Abstract PD6-02: The genomics of response to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer – Results from the ACOSOG Z1041 (Alliance) trial (2016) (0)
Combined modality approach in treatment of inflammatory carcinoma of the breast MD Anderson Cancer Center experience (1991) (0)
Imaging , Diagnosis , Prognosis Mammographic Breast Density Response to Aromatase Inhibition (2013) (0)
Preoperative chemotherapy for breast cancer. (2004) (0)
Evaluation of tamoxifen in chemotherapy resistant metastatic breast cancer (1978) (0)
Contents, Vol. 51, Supplement 1, 1994 (1994) (0)
Complete remission with combination chemotherapy in metastatic breast carcinoma. (1986) (0)
Phase II study of AMSA and doxorubicin to treat metastatic breast cancer. (1986) (0)
Prospective Randomized Trial of Neoadjuvant Fac vs. TFAC in Patients with Operable Breast Cancer: Impact of Taxane Chemotherapy on Locoregional Control (2009) (0)
Trilostane, an effective signal transduction inhibitor for advanced ER+ve and ER-ve post-menopausal breast cancer. (2004) (0)
Phase I Clinical and Pharmacological Study of Suppression of Human Antimouse Antibody Response to Monoclonal Antibody L6 by Deoxyspergualin1 (2006) (0)
Lapatinib Plus Letrozole May Improve Efficacy (2009) (0)
Comment on 'Long-term tamoxifen adjuvant therapy in node positive breast cancer'. (1985) (0)
Trastuzumab in the treatment of early-stage breast cancer (2006) (0)
Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer (2020) (0)
To the Editor.-Reply (1985) (0)
Biology of Aromatase (2003) (0)
Phase I evaluation of nafazatrom (1985) (0)
Phase I Clinical and Pharmacological Study of Suppression of Human Antimouse Antibody Response to Monoclonal Antibody L 6 by Deoxyspergualin 1 (2006) (0)
E17. Are aromatase inhibitors superior to tamoxifen after the menopause (2004) (0)
Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2‐positive breast cancer using an LC‐MALDI‐TOF/MS procedure (2011) (0)
2-HYDROXY-1 , 2 , 3-PROPANETRICARBOXYLATE ( [ 14 C ] TAS-108 ) AND ITS METABOLITES AFTER SINGLE ORAL ADMINISTRATION TO RATS BEARING 7 , 12-DIMETHYLBENZ ( ) ANTHRACENE-INDUCED MAMMARY TUMOR (2006) (0)
Osteolysis of the Clavicle-Reply (1988) (0)
Optimizing the Use of Aromatase Inhibitors (2009) (0)
13 ENDOCRINE THERAPY FOR BREAST CANCER (2001) (0)
A multi-center phase II study of three doses of TAS-108 in postmenopausal women with advanced breast carcinoma following first or second line endocrine therapy. (2009) (0)
Breast cancer in the elderly (1995) (0)
Lapatinib in HER2+ early breast cancer: Quality of life analysis. (2012) (0)
High-Dose Fulvestrant at Least as Good as Anastrozole in First-Line MBC (2009) (0)
Thep McCarthy/Swain article reviewed (2000) (0)
Commentary (Dawood/Buzdar): Systemic Treatment of Breast Cancer (2006) (0)
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy (2015) (0)
Letter from Our Readers (2007) (0)
Adjuvant endocrine therapy in postmenopausal breast cancers. Discussions (2003) (0)
Chapter 7 Combined endocrine and chemotherapy in breast cancer (2007) (0)
Commentary (Theriault/Buzdar): Pregnancy and Breast Cancer (2005) (0)
Letrozole improved disease-free survival in postmenopausal women after tamoxifen treatment for breast cancer (2004) (0)
Primary systemic therapy for operable breast cancer: present role and perspectives (2006) (0)
Abstract HER2-01: HER2-01 Clinical and Molecular Characteristics of HER2-low/zero Early Stage Triple-Negative Breast Cancer (2023) (0)
CYP19 GENE RESEQUENCING AND GENOTYPE DRUG RESPONSE-PHENOTYPE ASSOCIATION IN BREAST CANCER TREATED WITH NEOADJUVANT AROMATASE INHIBITORS. (2010) (0)
Explorer Functional Genetic Polymorphisms in the Aromatase Gene CYP 19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors (2017) (0)
Estrogen therapy and metastatic breast cancer. (Letter) (1977) (0)
Historical Development of Aromatase Inhibitors (2003) (0)
Author reply (0)
4 – PROGESTINS AND OTHER PREGNANE DERIVATIVES (1992) (0)
The Pritchard article reviewed (2000) (0)
Screening for cardiac risk before anthracycline administration: what are the real benefits? (2012) (0)
3-56 Docetaxel, Cisplatin, and Trastuzumab As Primary Systemic Therapy for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced Breast Cancer (2007) (0)
Recent developments and new directions in adjuvant therapy for breast cancer (1993) (0)
Prolongation of disease-free interval and survival with combined chemoimmunotherapy and irradiation of inflammatory breast carcinoma (1978) (0)
Pituitary ovarian function in patients with amenorrhea, during adjuvant chemoimmunotherapy for breast cancer (1977) (0)
Genes regulating estradiol and estrone-conjugate levels in postmenopausal women with resected early-stage breast cancer detected by a genome-wide association study (GWAS). (2011) (0)
In reply [14] (2005) (0)
A novel staging system for disease-specific survival in patients with breast cancer treated with surgery as the first intervention. (2011) (0)
Breast cancer in men. Authors' reply (2003) (0)
Abstract B21: Depression and quality of life in breast cancer survivors: 6–13 years postchemotherapy (2010) (0)
Unilateral lymphangitic carcinomatosis in breast cancer (1988) (0)
Development of Improved Aromatase Inhibitors (2003) (0)
The Hamilton/Volm article reviewed (2001) (0)
Pathologic Complete Response to Neoadjuvant Chemotherapy Plus Trastuzumab Predicts for Improved Survival in Women With HER2-positive Breast Cancer (2012) (0)
ATAC trial did not report interim results (2003) (0)
Women aged 35 years or younger with primary breast carcinoma: Disease features at presentation (2004) (0)
Paclitaxel in early breast cancer: a viewpoint by Aman U. Buzdar. (2004) (0)
Aromatase inhibitors in premenopausal breast cancer. (2012) (0)
Early-Stage Breast Cancer and Adjuvant Therapy (2005) (0)
ABCSG Trial: Survival Benefit for Tamoxifen → Anastrozole (2009) (0)
Non-invasive cardiac studies before and after adriamycin-containing adjuvant chemotherapy (FAC) for stages II and III breast cancer (1982) (0)
Taxol in metastatic breast cancer the MD Anderson Cancer Center experience (1994) (0)
Pregnancy and breast cancer: Epidemiology, treatment, and safety issues - Commentary (2005) (0)
In reply [18] (2005) (0)
1–42 A Randomized Trial of Exemestane After Two to Three Years of Tamoxifen Therapy in Postmenopausal Women With Primary Breast Cancer (2005) (0)
Effect of adjuvant trastuzumab (T) among patients treated with neoadjuvant T-based chemotherapy. (2014) (0)
Safety and tolerability of endocrine therapies used in the treatment of advanced breast cancer. (1999) (0)
Mitomycin-C and megestrol acetate - an active secondline regimen for breast cancer patients refractory to previous treatment (1978) (0)
Hepatic metastasis or granuloma. (1978) (0)
Phase I II, M ulticenter, D ouble-Blind, R andomized S tudy of L etrozole, a n A romatase I nhibitor, f or A dvanced B reast Cancer V ersus M egestrol A cetate (2001) (0)
Abstract P2-09-03: Mammographic Density Response to Aromatase Inhibitor Therapy (2010) (0)
Advances in endocrine therapy for early and advanced breast cancer (2003) (0)
Selection of Patients for Aromatase Inhibition Therapy (2003) (0)
Tamoxifen therapy for patients with breast cancer (2013) (0)
Erratum: (Hospital Pharmacy (October 1995) 45 (1335)) (1997) (0)
Sentinel L ymph N ode B iopsy I s A ccurate A fter N eoadjuvant Chemotherapy f or B reast C ancer (2000) (0)
Endocrine Therapy for Breast Cancer (2008) (0)
A short-term biomarker modulation prevention study of anastrazole in women at increased risk for breast cancer. (2009) (0)
3–37 Lumpectomy Plus Tamoxifen With or Without Irradiation in Women 70 Years of Age or Older With Early Breast Cancer (2005) (0)
In brief. (2008) (0)
In reply [12] (2005) (0)
The Seidman article reviewed (2006) (0)
Abstract C114: Androstenedione levels in postmenopausal women with resected early-stage breast cancer are associated with SNPs in CYP11B1 and CYP11B2 identified by a genome-wide association study (GWAS). (2011) (0)
Protecting Human Subjects from Risk in the Performance of Clinical Research and the Informed Consent Process (1999) (0)
Predictors o f L ocal-Regional R ecurrence A fter N eoadjuvant Chemotherapy a nd M astectomy W ithout R adiation (2002) (0)
Prediction of survival by degree of reactivity to BCG in patients with metastatic breast cancer. (1986) (0)
Fifteen-year Results of a Randomized Prospective Trial Comparing Hyperfractionated Versus Once-Daily Chest Wall Radiation After Chemotherapy and Mastectomy for Patients with Locally Advanced Non-Inflammatory Breast Cancer (2005) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Aman U. Buzdar?

Aman U. Buzdar is affiliated with the following schools: